Overview

Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's sumatriptan succinate 100 mg tablets to GSK's Imitrex® 100 mg tablets following a single, oral 100 mg (1 x 100 mg) dose administration under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Mylan Pharmaceuticals
Treatments:
Sumatriptan